Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold

Mikhail Krasavin, Alexey Lukin, Nikolay Zhurilo, Alexey Kovalenko, Ihor Zahanich, Sergey Zozulya, Daniel Moore, Irina G Tikhonova

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)
417 Downloads (Pure)


Free fatty acid receptor 1 (FFA1), previously known as GPR40 is a G protein-coupled receptor and a new target for treatment of type 2 diabetes. Two series of FFA1 agonists utilizing a 1,3,4-thiadiazole-2-caboxamide scaffold were synthetized. Both series offered significant improvement of the potency compared to the previously described 1,3,4-thiadiazole-based FFA1 agonists and high selectivity for FFA1. Molecular docking predicts new aromatic interactions with the receptor that improve agonist potency. The most potent compounds from both series were profiled for in vitro ADME properties (plasma and metabolic stability, LogD, plasma protein binding, hERG binding and CYP inhibition). One series suffered very rapid degradation in plasma and in presence of mouse liver microsomes. However, the other series delivered a lead compound that displayed a reasonable ADME profile together with the improved FFA1 potency.

Original languageEnglish
Pages (from-to)2954–2963
Number of pages10
JournalBioorganic & Medicinal Chemistry
Issue number13
Early online date05 May 2016
Publication statusPublished - 01 Jul 2016

Bibliographical note

Author was on holiday and forgot to upload in time.


Dive into the research topics of 'Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold'. Together they form a unique fingerprint.

Cite this